Evidence map›Paper›PMID 29256324›Full record

SynthesisJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2018

The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review.

Mathilde Mh Pauls, Barry Moynihan, Thomas R Barrick, Christina Kruuse, Jeremy B Madigan, Atticus H Hainsworth, Jeremy D Isaacs

Open access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. The PASTIS trial: Testing tadalafil for possible use in vascular cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Mathilde Mh Pauls1 Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.ORCID 0000-0003-1732-6325
Barry Moynihan2 Department of Neurology, St George's University Hospitals NHS Foundation Trust, London, UK.
Thomas R Barrick1 Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
Christina Kruuse4 Department of Neurology, Neurovascular Research Unit, Herlev Gentofte Hospital and University of Copenhagen, Denmark.
Jeremy B Madigan5 Department of Neuroradiology, St George's University Hospitals NHS Foundation Trust, London, UK.
Atticus H Hainsworth1 Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
Jeremy D Isaacs1 Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
St George's, University of London · GBSt George’s University Hospitals NHS Foundation Trust · GBUniversity of Copenhagen · DK

Funding

Medical Research Council MR/L023784/2National Centre for the Replacement, Refinement and Reduction of Animals in Research G0800701/1
6 · The paper itself

Abstract

Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension. We reviewed published data on the effects of phosphodiesterase-5 inhibitors on CBF in adult humans. A systematic review according to PRISMA guidelines was performed. Embase, Medline and Cochrane Library Trials databases were searched. Sixteen studies with 353 participants in total were retrieved. Studies included healthy volunteers and patients with migraine, ED, type 2 diabetes, stroke, pulmonary hypertension, Becker muscular dystrophy and subarachnoid haemorrhage. Most studies used middle cerebral artery flow velocity to estimate CBF. Few studies employed direct measurements of tissue perfusion. Resting CBF velocity was unaffected by phosphodiesterase-5 inhibitors, but cerebrovascular regulation was improved in ED, pulmonary hypertension, diabetes, Becker's and a group of healthy volunteers. This evidence suggests that phosphodiesterase-5 inhibitors improve responsiveness of the cerebral vasculature, particularly in disease states associated with an impaired endothelial dilatory response. This supports the potential therapeutic use of phosphodiesterase-5 inhibitors in vascular cognitive impairment where CBF is reduced. Further studies with better resolution of deep CBF are warranted. The review is registered on the PROSPERO database (registration number CRD42016029668).

Indexed as

AdultCerebrovascular CirculationDementia, VascularHumansPhosphodiesterase 5 InhibitorsPhosphodiesterase 5 InhibitorsCerebral blood flowdementiaphosphodiesterase-5 inhibitorssmall vessel diseasevascular cognitive impairment

Identifiers

PMID29256324
PMCPMC5951021
OpenAlexW2776013847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.